Eli Lilly Acquires RxPlus to Enhance Prescription Drug Adjudication Services in Canada

Eli Lilly and Company, a global pharmaceutical corporation, has announced the acquisition of Sudbury-based RxPlus, a leading company in the prescription drug adjudication market. This strategic move aims to improve healthcare outcomes and reduce costs through the integration of Lilly Canada's research expertise and RxPlus' advanced information technology. The combined resources of both companies will enable them to provide more comprehensive services to their customers.

Key Takeaways:

• Eli Lilly and Company has acquired RxPlus, a leading company in the prescription drug adjudication market in Canada.
• The acquisition is expected to enhance the management of pharmaceutical care and provide optimal health outcomes at affordable costs.
• RxPlus, a pharmacy benefit adjudicator, currently manages health benefits for approximately 500,000 Canadians.
• The combined resources of Lilly Canada and RxPlus will lead to more comprehensive services for their customers.
• The acquisition aims to provide better clinical and economic outcomes through the integration of Lilly Canada's research expertise and RxPlus' advanced information technology.
• RxPlus, under Lilly Canada's support, is poised for aggressive growth and rapid expansion of its customer base.

Statistics:

• 500,000 Canadians are currently managed by RxPlus for prescription drug benefits.
• $15 million: The amount of the research agreement signed by Eli Lilly and Allelix Biopharmaceuticals in January 1995.
• $25 million: The construction cost of Eli Lilly's new research center, which broke ground in April 1995.

Sources:

• "Eli Lilly Acquires RxPlus" (HealthWire, May 11, 1995)
• Eli Lilly and Company (press release, May 11, 1995)